Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. (14th November 2017)

• Record Type: Journal Article
• Authors: Li, Chi‐Chung; Dockendorf, Marissa; Kowalski, Ken; Yang, Bei; Xu, Yang; Xie, Iris; Kleijn, Huub Jan; Bosch, Rolien; Jones, Christopher; Thornton, Bob; Marcantonio, Eugene E.; Voss, Tiffini; Bateman, Kevin P.; Kothare, Prajakti A.
• Is Part Of: Journal of clinical pharmacology. Volume 58:Number 3(2018)
• Page Start: 294
• Page End: 303
• Publication Date: 2017-11-14
• Subjects: dried blood spots -- population PK -- CGRP antagonist -- MK‐1602 -- ubrogepant -- outpatient sampling; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1021
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Merck & Co., Inc. (Kenilworth, New Jersey) has recently published an integrated strategy for implementation of dried blood spots (DBS) in late‐stage trials for population pharmacokinetic (PK) modeling. We applied this strategy for another late‐stage clinical program: ubrogepant (MK‐1602), a novel oral calcitonin gene‐related peptide receptor antagonist for acute treatment of migraine. At the time of implementation, ubrogepant was entering phase 2 development. DBS was implemented to acquire PK information proximal to an acute migraine event to enable exposure–response modeling. The clinical endpoint was a spontaneous event, which generally occurs outside a clinic visit. Thus, an innovative feature of this trial was facilitating DBS in an outpatient setting. In vitro and bioanalytical tests established initial method feasibility and suitability for further evaluations in the clinic. A quantitative relationship was developed between blood and plasma concentrations from concurrently collected samples in a phase 1 (healthy subjects) and phase 2 (target patient population) study using graphical and population PK approaches. This integrated information was presented to the Food and Drug Administration for regulatory input. Following regulatory concurrence, DBS was poised for use in further clinical studies. Population PK modeling was used to dissect sources of variability contributing to DBS collection in the outpatient setting. What has been learned from this program has informed the broader integrated strategy of Merck & Co., Inc. (Kenilworth, NJ) for DBS implementation in clinical trials and research to improve the precision of PK data collected in an outpatient setting.